Make Better Decisions - Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

Get the Book: Make Better Decisions

Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

PDF eBook: Just $10 Get Print Book on Amazon

Serving leading biopharmaceutical companies globally:

McKesson
Boehringer Ingelheim
Dow
Moodys
Johnson and Johnson
Mallinckrodt

Last Updated: December 7, 2019

DrugPatentWatch Database Preview

Details for New Drug Application (NDA): 021036

See Plans and Pricing

« Back to Dashboard

NDA 021036 describes RELENZA, which is a drug marketed by Glaxosmithkline and is included in one NDA. It is available from one supplier. Additional details are available on the RELENZA profile page.

The generic ingredient in RELENZA is zanamivir. One supplier is listed for this compound. Additional details are available on the zanamivir profile page.
Summary for 021036
Tradename:RELENZA
Applicant:Glaxosmithkline
Ingredient:zanamivir
Patents:0
Formulation / Manufacturing:see details
Pharmacology for NDA: 021036
Mechanism of ActionNeuraminidase Inhibitors
Medical Subject Heading (MeSH) Categories for 021036
Suppliers and Packaging for NDA: 021036
Tradename Generic Name Dosage NDA Application Type Supplier National Drug Code Package Code Package
RELENZA zanamivir POWDER;INHALATION 021036 NDA GlaxoSmithKline LLC 0173-0681 0173-0681-01 5 PACKAGE in 1 CARTON (0173-0681-01) > 4 POWDER in 1 PACKAGE

Profile for product number 001

Active Rx/OTC/Discontinued:RXDosage:POWDER;INHALATIONStrength5MG
Approval Date:Jul 26, 1999TE:RLD:Yes

Expired US Patents for NDA 021036

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Glaxosmithkline RELENZA zanamivir POWDER;INHALATION 021036-001 Jul 26, 1999   Start Trial   Start Trial
Glaxosmithkline RELENZA zanamivir POWDER;INHALATION 021036-001 Jul 26, 1999   Start Trial   Start Trial
Glaxosmithkline RELENZA zanamivir POWDER;INHALATION 021036-001 Jul 26, 1999   Start Trial   Start Trial
Glaxosmithkline RELENZA zanamivir POWDER;INHALATION 021036-001 Jul 26, 1999   Start Trial   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Patent No. >Patent Expiration

Complete Access Available with Subscription

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

McKesson
Medtronic
Moodys
Express Scripts
Mallinckrodt
McKinsey

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.